Literature DB >> 10348094

Cyclosporin-induced hypertension: incidence, pathogenesis and management.

S J Taler1, S C Textor, V J Canzanello, L Schwartz.   

Abstract

Blood pressure increases soon after administration of immunosuppressive regimens using cyclosporin. Characteristic vascular changes lead to systemic and renal vasoconstriction. Changes in blood pressure are commonly associated with disturbed circadian regulation and may promote the rapid development of target organ injury, including intracranial haemorrhage, left ventricular hypertrophy and microangiopathic haemolysis. The mechanisms underlying this disorder are complex and include altered vascular endothelial function. Vasodilators such as prostacyclin and nitric oxide are suppressed, whereas vasoconstrictors, including endothelin, are increased. Changes in the kidney include vasoconstriction, reduced glomerular filtration and sodium retention. Effective therapy depends upon rigorous blood pressure control by administration of vasodilating agents, with attention to potential interactions with cyclosporin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348094     DOI: 10.2165/00002018-199920050-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  66 in total

1.  Increased endothelin level after cyclosporine therapy.

Authors:  G Deray; A Carayon; P Le Hoang
Journal:  Ann Intern Med       Date:  1991-05-01       Impact factor: 25.391

2.  Renal hemodynamics, urinary eicosanoids, and endothelin after liver transplantation.

Authors:  S C Textor; D J Wilson; A Lerman; J C Romero; J C Burnett; R Wiesner; E R Dickson; R A Krom
Journal:  Transplantation       Date:  1992-07       Impact factor: 4.939

3.  Acute cyclosporine renal dysfunction reversed by dopamine infusion in healthy subjects.

Authors:  G Conte; A Dal Canton; M Sabbatini; P Napodano; L De Nicola; G Gigliotti; G Fuiano; A Testa; C Esposito; D Russo
Journal:  Kidney Int       Date:  1989-12       Impact factor: 10.612

4.  Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation.

Authors:  S C Textor; J C Burnett; J C Romero; V J Canzanello; S J Taler; R Wiesner; M Porayko; R Krom; G Gores; E Hay
Journal:  Kidney Int       Date:  1995-05       Impact factor: 10.612

5.  Abnormal diurnal variation of blood pressure, cardiac output, and vascular resistance in cardiac transplant recipients.

Authors:  R N Idema; A H van den Meiracker; A H Balk; E Bos; M A Schalekamp; A J Man in 't Veld
Journal:  Circulation       Date:  1994-12       Impact factor: 29.690

6.  Suppression of plasma renin activity by cyclosporine.

Authors:  J P Bantle; R J Boudreau; T F Ferris
Journal:  Am J Med       Date:  1987-07       Impact factor: 4.965

7.  Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension.

Authors:  K Shimada; A Kawamoto; K Matsubayashi; M Nishinaga; S Kimura; T Ozawa
Journal:  J Hypertens       Date:  1992-08       Impact factor: 4.844

8.  Exogenous glucocorticoid eliminates or reverses circadian blood pressure variations.

Authors:  Y Imai; K Abe; S Sasaki; N Minami; M Munakata; M Nihei; H Sekino; K Yoshinaga
Journal:  J Hypertens       Date:  1989-02       Impact factor: 4.844

9.  Blood pressure and endocrine responses to changes in dietary sodium intake in cardiac transplant recipients. Implications for the control of sodium balance.

Authors:  D R Singer; N D Markandu; M G Buckley; M A Miller; G A Sagnella; D R Lachno; F P Cappuccio; A Murday; M H Yacoub; G A MacGregor
Journal:  Circulation       Date:  1994-03       Impact factor: 29.690

10.  Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trail.

Authors:  S C Brozena; M R Johnson; H Ventura; R Hobbs; L Miller; M T Olivari; B Clemson; R Bourge; R Quigg; R M Mills; D Naftel
Journal:  J Am Coll Cardiol       Date:  1996-06       Impact factor: 24.094

View more
  21 in total

1.  Management of Corneal Graft Rejection - A Case Series Report and Review of the Literature.

Authors:  Pho Nguyen; Felise Barte; Shuntaro Shinada; Samuel C Yiu
Journal:  J Clin Exp Ophthalmol       Date:  2010-09-29

2.  Left ventricle geometry remolding after heart transplantation: a two-dimensional ultrasound study.

Authors:  Xiao-Juan Qin; He Li; Jun You; Qing Lv; Jing Zhang; Han-Jing Gao; Ming-Xing Xie
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-12-13

3.  Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty.

Authors:  Jong Joo Lee; Mee Kum Kim; Won Ryang Wee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-21       Impact factor: 3.117

Review 4.  Central modulation of cyclosporine-induced hypertension.

Authors:  Hanan M El-Gowelli; Mahmoud M El-Mas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-29       Impact factor: 3.000

Review 5.  Mitochondrial injury and dysfunction in hypertension-induced cardiac damage.

Authors:  Alfonso Eirin; Amir Lerman; Lilach O Lerman
Journal:  Eur Heart J       Date:  2014-11-10       Impact factor: 29.983

Review 6.  Hypertension in Kidney Transplant Recipients: Where Are We Today?

Authors:  Elif Ari; Francesco Fici; Nicolas Roberto Robles
Journal:  Curr Hypertens Rep       Date:  2021-04-13       Impact factor: 5.369

7.  PP2B-dependent NO production in the medullary thick ascending limb during diabetes.

Authors:  Jan M Foster; Pamela K Carmines; Jennifer S Pollock
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-20

Review 8.  Drug-induced cardiovascular disorders.

Authors:  C Aengus Murphy; Henry J Dargie
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Urinary levels of matrix metalloproteinases and their tissue inhibitors in nephrotic children.

Authors:  Anna M Wasilewska; Walentyna M Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2008-07-02       Impact factor: 3.714

10.  Antihypertensive agents and renal transplantation.

Authors:  G Vergoulas
Journal:  Hippokratia       Date:  2007-01       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.